Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)

Di Mario, Carlo, Bolognese, Leonardo, Maillard, Luc, Dudek, Dariusz, Gambarati, Giampaolo, Manari, Antonio, Guiducci, Vincenzo, Patrizi, Giampiero, Rusconi, Luigi Cesare, Piovaccari, Giancarlo, Hibon, Agnes Ricard, Belpomme, Vanessa, Indolfi, Ciro, Olivari, Zoran, Steffenino, Giuseppe, Zmudka, Krzysztof, Airoldi, Flavio, Panzarasa, Rita, Flather, Marcus and Steg, Philippe Gabriel (2004) Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). American Heart Journal, 148 (3). pp. 378-85. ISSN 0002-8703

Full text not available from this repository. (Request a copy)


Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.

Item Type: Article
Uncontrolled Keywords: antibodies, monoclonal,cost-benefit analysis,drug therapy, combination,emergency medical services,humans,immunoglobulin fab fragments,myocardial infarction,plasminogen activators,platelet glycoprotein gpiib-iiia complex,prospective studies,recombinant proteins,recurrence,stents,thrombolytic therapy,tissue plasminogen activator,treatment outcome
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:16
Last Modified: 24 Oct 2022 05:37
DOI: 10.1016/j.ahj.2004.03.038

Actions (login required)

View Item View Item